|
Vol. 10.40 – 13 October, 2021
|
|
|
|
|
|
Silencing of SOX9 decreased cell proliferation, induced G1/S arrest and increased apoptosis of diffuse large B-cell lymphoma cells, both in vitro and in vivo. [Blood]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
The authors interrogated gene expression profiles from glioblastoma stem cells, differentiated glioblastoma cells, and neural stem cells, revealing EYA2 as preferentially expressed by GSCs.
[Journal of Experimental Medicine]
|
|
|
|
|
Based on an integrative analysis of The Cancer Genome Atlas database, investigators identified long non-coding RNA-RNA Component of Mitochondrial RNA Processing Endoribonuclease (RMRP) as one of the most highly upregulated lncRNAs that awas associated with poor survival in non-small cell lung cancer.
[Cell Death & Differentiation]
|
|
|
|
|
To identify genetic vulnerabilities of colon cancer, scientists performed targeted CRISPR dropout screens comprising 657 Drugbank targets and 317 epigenetic regulators on two patient-derived colon CSCs-enriched spheroids.
[Oncogene]
|
|
|
|
|
Investigators examined the impact of patient age, sex, stage, and tumor type on circulating-free DNA yield, circulating-tumor DNA fraction, and estimated ctDNA quantity from a large cohort of clinical liquid biopsy samples.
[Clinical Chemistry]
|
|
|
|
|
Researchers investigated the mechanical phenotype of the human colon adenocarcinoma cell, HT29, which is known to be a heterogeneous cell line with both multipotency and self-renewal abilities.
[Analytical Chemistry]
|
|
|
|
|
The authors explored the role of F-box and WD repeat domain containing 11 (FBXW11) in the development and metastasis of colorectal cancer (CRC). FBXW11 was overexpressed in colorectal tumor tissues and its overexpression was associated with a poor prognosis of CRC patients.
[Cell Death & Disease]
|
|
|
|
|
Scientists studied the role of the Par3 protein (encoded by PARD3) in glioblastoma multiforme (GBM). GBM patient transcriptomic data and patient-derived culture analysis indicated diverse levels of expression of PARD3 across and independent from subtypes. [Cell Death & Disease]
|
|
|
|
|
Investigators found that the stemness characteristics of lung cancer cells were significantly enhanced by the overexpression of non-muscle myosin heavy chain 9 (MYH9), and the knockout of MYH9 had the opposite effects. [Cell Death Discovery]
|
|
|
|
|
|
Scientists discuss the roles of circadian rhythms in cancer pathogenesis, highlighting the recent advances in chronotherapeutic approaches for improved cancer treatment.
[Experimental & Molecular Medicine]
|
|
|
|
|
The authors discuss CSC molecular regulation, signaling pathways, methods for the study of the topic, as well as molecules and drugs capacity of inhibiting the interplay of hypoxia-CSC. [Molecular Biology Reports]
|
|
|
|
|
Investigators review recent evidence supporting roles for Delta-like homologue 1 (DLK1) in the maintenance of aggressive stem cell characteristics of tumor cells, specifically focusing on central nervous system tumors, neuroblastoma, and hepatocellular carcinoma. [Journal of Histochemistry & Cytochemistry]
|
|
|
|
|
|
Lixte Biotechnology Holdings, Inc. announced entry into a collaboration with the Netherlands Cancer Institute, Amsterdam, and Oncode Institute, Utrecht to identify the most promising drugs to be combined with LB-100, and potentially LB-100 analogues, to be used to treat a range of cancers.
[Lixte Biotechnology Holdings, Inc.]
|
|
|
|
|
Precirix NV announced that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for the treatment of HER2-positive metastatic cancer. The trial will evaluate CAM-H2 in HER2-positive metastatic breast and gastric/gastro-esophageal cancer patients. [Precirix NV]
|
|
|
|
|
|
November 3 – 5, 2021 Lleida, Spain
|
|
|
|
|
|
|
University of Manitoba – Winnipeg, Manitoba, Canada
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
City of Hope – Los Angeles, California, United States
|
|
|
|
|
Massachusetts General Hospital – Boston, Massachusetts, United States
|
|
|
|
|
German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany
|
|
|
|
|